| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
N6-(2-Hydroxyethyl)adenosine targets purine nucleoside metabolism and signaling pathways. The compound inhibits the NF-κB/Smad signaling pathway. As a purine nucleoside analog, the compound can be incorporated into nucleic acids or interfere with purine metabolism. The anticancer mechanism relies on inhibiting DNA synthesis and inducing apoptosis.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, N6-(2-Hydroxyethyl)adenosine can be used to study purine nucleoside metabolism and signaling. The compound's effects on NF-κB/Smad signaling can be assessed in cell-free systems using purified components or reporter assays.
|
| ln Vivo |
In cell-based assays, N6-(2-Hydroxyethyl)adenosine exhibits broad antitumor activity targeting indolent lymphoid malignancies. The compound inhibits DNA synthesis and induces apoptosis in cancer cells. It also inhibits the NF-κB/Smad signaling pathway and exhibits anti-hyperglycemia, antioxidant, anti-inflammatory, and insecticidal activities.
|
| Enzyme Assay |
The cell-free assay for studying N6-(2-Hydroxyethyl)adenosine involves measuring its effects on signaling pathways or enzyme activities. The compound's effects on NF-κB/Smad signaling can be assessed using in vitro kinase assays or protein-protein interaction studies. The inhibition of DNA synthesis can be measured using cell-free DNA polymerase assays.
|
| Cell Assay |
Cell-based assays for anti-tumor activity involve culturing cancer cell lines and treating them with N6-(2-Hydroxyethyl)adenosine at concentrations ranging from 0.1 to 100 μM. Cells are incubated for 24-72 hours, and cell viability is assessed using MTT or CCK-8 assays. Apoptosis is assessed by Annexin V staining or caspase activity assays. The effect on NF-κB/Smad signaling is assessed by Western blotting or reporter assays.
|
| Animal Protocol |
There is no established animal experimental protocol for N6-(2-Hydroxyethyl)adenosine specifically. As a purine nucleoside analog with antitumor activity, the compound could potentially be evaluated in animal models of cancer.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N6-(2-Hydroxyethyl)adenosine have not been extensively reported. As a small molecule with molecular weight of 311.29 g/mol, the compound would be expected to have reasonable bioavailability and tissue penetration. Further pharmacokinetic studies would be required.
|
| Toxicity/Toxicokinetics |
Toxicity data for N6-(2-Hydroxyethyl)adenosine are not well documented. As a purine nucleoside analog, the compound may have effects on normal cells as well as cancer cells. Standard toxicity studies would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
Reports indicate that (2R,3R,4S,5R)-2-(6-((2-hydroxyethyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol has been found in Isaria japonica, Cordyceps pruinosa, and Micromeles japonica, and related data are available.
N6-(2-Hydroxyethyl)adenosine is a research compound with broad biological activities including antitumor, anti-inflammatory, antioxidant, and anti-hyperglycemia effects. It is a purine nucleoside analog that inhibits DNA synthesis and induces apoptosis. It is not an approved pharmaceutical and has no clinical trial history. This product is intended for research use only. |
| Molecular Formula |
C12H17N5O5
|
|---|---|
| Molecular Weight |
311.29
|
| Exact Mass |
311.123
|
| CAS # |
4338-48-1
|
| PubChem CID |
96124
|
| Appearance |
White to off-white solid powder
|
| Density |
1.88g/cm3
|
| Boiling Point |
725.8ºC at 760 mmHg
|
| Melting Point |
194-195ºC
|
| Flash Point |
392.7ºC
|
| Index of Refraction |
1.806
|
| LogP |
-1.1
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
378
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)NCCO
|
| InChi Key |
BBOCDRLDMQHWJP-WOUKDFQISA-N
|
| InChi Code |
InChI=1S/C12H17N5O5/c18-2-1-13-10-7-11(15-4-14-10)17(5-16-7)12-9(21)8(20)6(3-19)22-12/h4-6,8-9,12,18-21H,1-3H2,(H,13,14,15)/t6-,8-,9-,12-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-[6-(2-hydroxyethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~321.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (8.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2124 mL | 16.0622 mL | 32.1244 mL | |
| 5 mM | 0.6425 mL | 3.2124 mL | 6.4249 mL | |
| 10 mM | 0.3212 mL | 1.6062 mL | 3.2124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
